Answers are grounded in this paper and cite their sources.
Case report shows clinical recovery in fulminant myocarditis with ruxolitinib, indicating immune modulation and novel therapeutic approach.
Description Acute fulminant myocarditis (AFM) represents a severe inflammatory cardiac condition with limited therapeutic options. We evaluated JAK/STAT pathway inhibition as a novel therapeutic strategy in AFM through detailed immunological profiling. In a patient with biopsy-confirmed AFM presenting with cardiogenic shock, administration of ruxolitinib (10mg BID) led to rapid clinical improvement. Comprehensive single-cell analyses, including RNA-seq, CITE-seq, and TCR/BCR-seq, revealed pre-treatment hyperactivation of JAK/STAT signaling in specific immune populations. Post-treatment analyses demonstrated significant suppression of interferon-stimulated genes in myeloid cells, reduction in cytotoxic lymphocyte populations, and restoration of physiologic immune TCR/BCR homeostasis, correlating with clinical recovery. These findings establish JAK inhibition as a promising therapeutic approach in AFM and provide mechanistic insights into immune modulation in cardiac inflammation.
No takes yet. Share an insight, caveat, or question.
Juan Qin (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: